Argos Therapeutics, Inc. (ARGS) Presents New Data From Clinical Research For AGS-004 Patient-Specific Immunotherapy In Treatment Of HIV
3/5/2014 9:08:21 AM
DURHAM, N.C., March 4, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. Results were presented in two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Boston.
Help employers find you! Check out all the jobs and post your resume.
comments powered by